Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: PROTO-ONCOGENE PROTEINS B-RAF - METABOLISM , . Treffer: 9

2016

Dernayka, L; Rauch, N; Jarboui, MA; Zebisch, A; Texier, Y; Horn, N; Romano, D; Gloeckner, CJ; Kriegsheim, Av; Ueffing, M; Kolch, W; Boldt, K Autophosphorylation on S614 inhibits the activity and the transforming potential of BRAF.
Cell Signal. 2016; 28(9):1432-1439
Web of Science PubMed FullText FullText_MUG

 

2015

Mössner, R; Zimmer, L; Berking, C; Hoeller, C; Loquai, C; Richtig, E; Kähler, KC; Hassel, JC; Gutzmer, R; Ugurel, S Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.
J Eur Acad Dermatol Venereol. 2015; 29(9):1797-1806 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2014

Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410
Web of Science PubMed FullText FullText_MUG

 

2013

Busam, KJ; Sung, J; Wiesner, T; von Deimling, A; Jungbluth, A Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes.
Am J Surg Pathol. 2013; 37(2):193-199
Web of Science PubMed FullText FullText_MUG

 

2012

Wiesner, T; Murali, R; Fried, I; Cerroni, L; Busam, K; Kutzner, H; Bastian, BC A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.
Am J Surg Pathol. 2012; 36(6):818-830 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2010

Schrama, D; Kneitz, H; Willmes, C; Adam, C; Houben, R; Becker, JC Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma.
J Invest Dermatol. 2010; 130(3):897-898 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Houben, R; Ortmann, S; Drasche, A; Troppmair, J; Herold, MJ; Becker, JC Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
J Invest Dermatol. 2009; 129(2):406-414 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2008

Houben, R; Vetter-Kauczok, CS; Ortmann, S; Rapp, UR; Broecker, EB; Becker, JC Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
J Invest Dermatol. 2008; 128(8):2003-2012 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Hoek, KS; Schlegel, NC; Brafford, P; Sucker, A; Ugurel, S; Kumar, R; Weber, BL; Nathanson, KL; Phillips, DJ; Herlyn, M; Schadendorf, D; Dummer, R Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 2006; 19(4):290-302
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Med Uni Graz Impressum